DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2007/0003580 A1 Loria Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2007/0003580 A1 Loria Et Al US 20070003580A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0003580 A1 Loria et al. (43) Pub. Date: Jan. 4, 2007 (54) ANTI-ALLERGIC PHARMACEUTICAL (30) Foreign Application Priority Data COMPOSITION CONTAINING AT LEAST ONE ALLERGEN AND AT LEAST ONE Mar. 30, 2001 (FR)............................................ O1/O437O ANTHSTAMINE COMPOUND May 3, 2001 (FR)............................................ O1/O5929 (76) Inventors: Emile Loria, La Jolla, CA (US); Publication Classification Gaetan Terrasse, Saint-Valier (FR); Yves Trehin, Toulouse (FR) (51) Int. Cl. A6IR 39/36 (2006.01) Correspondence Address: A6II 3L/495 (2006.01) MANDEL & ADRANO A61K 31/4172 (2006.01) SS SOUTH LAKEAVENUE A6II 3/473 (2006.01) SUTE 710 (52) U.S. Cl. ................ 424/275.1: 514/255.04: 514/400; PASADENA, CA 91101 (US) 514/290 (21) Appl. No.: 11/413,489 (57) ABSTRACT (22) Filed: Apr. 28, 2006 The present invention relates to an anti-allergic pharmaceu tical composition containing at least two active agents Related U.S. Application Data chosen from: (i) one allergen, (ii) one antihistamine com pound, and (iii) one inhibitor of histamine synthesis, said (63) Continuation-in-part of application No. 09/867,159, active agents being associated in said composition with a filed on May 29, 2001, now Pat. No. 7,048,928. pharmaceutically acceptable vehicle. US 2007/0003580 A1 Jan. 4, 2007 ANT-ALLERGIC PHARMACEUTICAL seen in atopic persons in whom allergic reactions are severe COMPOSITION CONTAINING AT LEAST ONE owing to the high level of Th2 clones promoting the Syn ALLERGEN AND AT LEAST ONE thesis of IgE. ANTHSTAMINE COMPOUND 0015 The general reaction observed subsequent to the 0001. This application is a continuation-in-part of U.S. penetration of the new allergen is not due to its toxicity but application Ser. No. 09/867,159, filed May 29, 2001, which simply to the fact that the triggering level of allergic claims the priority of French Application No. 01/04370 filed phenomena is very low, helped by other sensitizations. Mar. 30, 2001 and French Application No. 01/05929 filed May 3, 2001, the contents of which are hereby incorporated 0016. An allergy is a reaction due to hypersynthesis of by reference, in their entirety, into this application, and from IgE immunoglobulins. The inflammatory reaction chiefly which priority is hereby claimed. affects the respiratory and ENT spheres, with pathological focalization at the nose, lungs and skin. Pathologies asso 0002 Throughout this application various publications ciated with the allergy are invalidating and suffer from the are referenced. The disclosures of these publications in their lack of efficacy of conventional treatment. There is no entireties are hereby incorporated by reference into this preventive strategy and curative means are insufficient or ill application in order to more fully describe the state of the art used. to which the invention pertains. 0017. The usual treatment of allergic disease consists, BACKGROUND OF THE INVENTION during a first phase, of identifying the allergen responsible: 0003. The present invention relates to new pharmaceuti dust mites, pollen, mold, food. The second phase comprises cal compositions for the prevention and treatment of aller removal measures. The third treatment phase focuses on the gies. Allergies are a scourge which affects 25% of the target organ which appears to be symptomatic: ENT treat world's population. This number is on the increase in ment for rhinitis, anti-asthmatic treatment if the affected connection with growing environmental toxicity (dust, food, sphere is respiratory, dermatological treatment if the affected motor vehicles). In addition, a person’s risk of Suffering areas are skin areas. from allergy is increased if there is a previous family history 0018. In the event of failure of the preceding measures, of allergy. individual or complementary treatment may be offered 0004 The biological mechanism of allergies may be through the choice of a specific immunotherapy (specific described as an abnormally amplified reaction to the entry of pollen, specific acarid, specific mould). The complexity of an allergen into the body. The following events account for the treatment instituted often leads to poor patient compli the reaction: ance, and therefore, failure to the treatment. 0005) identification of the allergen by the body, 0019. The purpose of the present invention is precisely to offer new means of treating allergies that are both preventive 0006) secretion of cytokines in response to allergen pen and curative. etration, 0007 conversion of Th1 cells into Th2 cells, with the SUMMARY OF THE INVENTION production of clones specific to the antigen, 0020. The present invention provides pharmaceutical 0008 the Th2 cells synthesize interleukins 4 and 13, compositions (e.g., in a semisolid or liquid dosage form) that responsible for aggravation of the allergic symptoms are, e.g., anti-allergic. In one embodiment, the pharmaceu through an upsurge in IgE synthesis, tical composition comprises an allergen, and an antihista mine compound. In another embodiment, the pharmaceuti 0009 the terminal phase of the reaction is the release cal composition comprises an allergen and an inhibitor of of histamine and serotonin having a recruiting effect on histamine synthesis. In a further embodiment, the pharma the Th2 clones, ceutical composition comprises an antihistamine compound 0010 toxic and inflammatory self-maintaining reac and an inhibitor of histamine synthesis. In a further embodi tion, even without any antigen stimulation. ment, the pharmaceutical composition comprises an aller gen, an antihistamine compound, and an inhibitor of hista 0011. The antigen-presenting cells (APCs: macrophages, mine synthesis. Additionally, said pharmaceutical dendritic cells, B-lymphocytes) take part in the reaction of composition comprises a pharmaceutically acceptable car hypersensitivity through basic cell cooperation carrying the rier or vehicle. immune reaction further. Allergies belong to the nonself class of defense mechanisms. 0021 Additionally, the present invention provides meth ods for inhibiting, preventing, or treating allergic symptoms 0012. The main allergens are acarids (dust mites) (80%) comprising administering: (i) an allergen, and an antihista and pollens (20%). mine compound, (ii) an allergen and an inhibitor of hista 0013 The self-stimulating reactions of specific APC mine synthesis, (iii) an antihistamine compound and an clones have an effect on the general rate of release of inhibitor of histamine synthesis, or (iv) an allergen, an histamine and serotonin leading to an aggravation of the antihistamine compound, and an inhibitor of histamine general clinical symptomatology. synthesis. 0014. The recruitment level of new IgE-secreting cells is 0022. The allergen, antihistamine compound, and inhibi thereby increased facilitating the explosion of clinical signs tor of histamine synthesis can be administered sequentially when a new allergen penetrates inside the body. This can be (in any order) or concurrently. Further, more than one US 2007/0003580 A1 Jan. 4, 2007 allergen, antihistamine compound, and/or inhibitor of his administered to a subject, the composition may be metabo tamine synthesis can be used or administered. lized thus enabling release of peptides from the allergen and other chemical Substances from the composition in an inde DETAILED DESCRIPTION OF THE pendent manner at galenic (i.e., pharmaceutically effective INVENTION dosage) level(s). The peptides so released can be complete or partial amino acid sequences (fragments) that are part of Compositions of the Invention the allergen that can bind MHC molecules and trigger an 0023 The present invention provides pharmaceutical immunological response. compositions (e.g., anti-allergic compositions) containing 0028 Advantageously, said allergen may be chosen from two or more active agents of the invention chosen from among the major antigens or mixture of major antigens of among: (i) an allergen, (ii) an antihistamine compound, and acarids able to induce an immune reaction. Alternatively, the (iii) an inhibitor of histamine synthesis (agents of the allergen may be a nucleic acid that encodes the major invention). Said agents of the invention may be associated in antigens or mixture of major antigens of acarids able to said composition with a pharmaceutically acceptable carrier induce an immune reaction. Indeed, one embodiment of the or vehicle. Pharmaceutically acceptable carrier or vehicle invention involved using ubiquitous antigens of acarids. refers to a non-toxic solid, semisolid (also referred to herein These antigens are present in Substantial quantity in the as Softgel) or liquid filler, diluent, encapsulating material or environment and are the cause of the development of allergic formulation auxiliary of any type. The invention also pro reactions in the world. For example, two acarids, Dermato vides methods for treating or preventing of allergy using said goides Pteronyssinus (DP) and Dermatogoides Farinae compositions. (DF) are the most represented in the world environment. 0024. A first preferred embodiment of an anti-allergic 0029. In accordance with the invention, the allergens pharmaceutical composition according to the invention con used in the compositions of the invention may either be tains (i) at least one allergen and (ii) at least one antihista extracts obtained from crude biological material (e.g., mine compound, in a pharmaceutically acceptable
Load more

Recommended publications
  • Intranasal Rhinitis Agents
    Intranasal Rhinitis Agents Therapeutic Class Review (TCR) February 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected].
    [Show full text]
  • Download Article (PDF)
    Use of astemizole in a large group practice TIMOTHY J. CRAIG, DO MARK GREENWALD, MD VANESSA KAUFFMANN JILL CRAIG, MS Astemizole was released in 1988. Shortly after the release of astemizole and terfe­ In late 1992, a new warning label was added nadine, it became evident that both were associat­ in response to reports of syncope and death ed with prolonged QT intervals and arrhythmias, from arrhythmia. Records of patients given new mainly torsades de pointes. Because of this associ­ prescriptions for astemizole were reviewed ation, the Food and Drug Administration (FDA) and to assess compliance with the warnings in a the manufacturers provided a warning letter to large multispecialty practice. The indication physicians in 1992.1 For astemizole, the warning was appropriate in 89% of cases. Excessive stated: (1) That arrhythmias have usually occurred doses were used in 4% of cases. Two percent when the dose of 10 mg/d (the recommended dose) of prescriptions were given to patients with was exceeded. Exceeding this dose and the use of contraindications. Only two complications loading doses should be avoided. (2) Serum levels were documented. Despite carrying a drug of astemizole may be elevated by ketoconazole, ery­ warning, astemizole continues to be used thromycin;, and itraconazole. These drugs should inappropriately and is a medicolegal concern. not be used together. (3) Presyncope and syncope Education and drug evaluations can be used may precede fatal arrhythmias and calls for dis­ to enhance compliance and decrease the risk continuing astemizole. (4) The drug should be avoid­ associated with the use of astemizole. ed in patients with significant liver disease.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130210835A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2013/0210835 A1 Mitchell (43) Pub. Date: Aug. 15, 2013 (54) PHARMACEUTICAL COMPOSITIONS Publication Classi?cation (75) Inventor: Odes W. Mitchell; Arlington, TX (U S) (51) Int. Cl. A61K31/137 (2006.01) _ A611; 31/4402 (2006.01) (73) Ass1gnee: GM PHARMACEUTICAL, INC, A61K 31/485 (200601) Arhngton, TX (Us) A611; 31/09 (2006.01) _ A611; 31/495 (2006.01) (21) App1.No.. 13/703,584 A61K31/505 (200601) 22 PCT P1 d: J .13 2011 (52) us Cl ( ) 1e “n ’ CPC ........... .. A611; 31/137 (2013.01); A611;31/495 (86) PCT NO. PCT/“11,4031 (2013.01); A611;31/505 (2013.01); A611; 31/485 (2013.01); A611; 31/09 (2013.01); § 371 (0)0). A611;31/4402 (2013.01) (2), (4) Date: Feb- 2, 2013 USPC .... .. 514/255.04; 564/355; 514/653; 544/396; 544/332; 514/275; 546/74; 514/289; 514/282; Related US. Application Data 514657; 514652 (60) Provisional application No. 61/354,061; ?led on Jun. (57) ABSTRACT 11; 2010; provisional application No. 61/354,057; A composition of an antitussive; a decongestant; or an anti ?led on Jun. 11; 2010; provisional application No. histamine to treat respiratory and oral pharyngeal congestion 61/354,053; ?led on Jun. 11,2010. and related symptoms in a patient. US 2013/0210835 A1 Aug. 15,2013 PHARMACEUTICAL COMPOSITIONS mucus build-up to clear congestion in the air passages. Symp toms due to allergies or allergens are often treated With an CROSS-REFERENCES TO RELATED antihistamine.
    [Show full text]
  • Antihistamine Therapy in Allergic Rhinitis
    CLINICAL REVIEW Antihistamine Therapy in Allergic Rhinitis Paul R. Tarnasky, MD, and Paul P. Van Arsdel, Jr, MD Seattle, Washington Allergic rhinitis is a common disorder that is associated with a high incidence of mor­ bidity and considerable costs. The symptoms of allergic rhinitis are primarily depen­ dent upon the tissue effects of histamine. Antihistamines are the mainstay of therapy for allergic rhinitis. Recently, a second generation of antihistamines has become available. These agents lack the adverse effect of sedation, which is commonly associated with older antihistamines. Current practice of antihistamine therapy in allergic rhinitis often involves random selection among the various agents. Based upon the available clinical trials, chlorpheniramine appears to be the most reasonable initial antihistaminic agent. A nonsedating antihis­ tamine should be used initially if a patient is involved in activities where drowsiness is dangerous. In this comprehensive review of allergic rhinitis and its treatment, the cur­ rent as well as future options in antihistamine pharmacotherapy are emphasized. J Fam Pract 1990; 30:71-80. llergic rhinitis is a common condition afflicting some­ defined by the period of exposure to those agents to which A where between 15 and 30 million people in the United a patient is sensitive. Allergens in seasonal allergic rhinitis States.1-3 The prevalence of disease among adolescents is consist of pollens from nonflowering plants such as trees, estimated to be 20% to 30%. Two thirds of the adult grasses, and weeds. These pollens generally create symp­ allergic rhinitis patients are under 30 years of age.4-6 Con­ toms in early spring, late spring through early summer, sequently, considerable costs are incurred in days lost and fall, respectively.
    [Show full text]
  • Medicines Classification Committee
    Medicines Classification Committee Meeting date 1 May 2017 58th Meeting Title Reclassification of Sedating Antihistamines Medsafe Pharmacovigilance Submitted by Paper type For decision Team Proposal for The Medicines Adverse Reactions Committee (MARC) recommended that the reclassification to committee consider reclassifying sedating antihistamines to prescription prescription medicines when used in children under 6 years of age for the treatment of medicine for some nausea and vomiting and travel sickness [exact wording to be determined by indications the committee]. Reason for The purpose of this document is to provide the committee with an overview submission of the information provided to the MARC about safety concerns associated with sedating antihistamines and reasons for recommendations. Associated March 2013 Children and Sedating Antihistamines Prescriber Update articles February 2010 Cough and cold medicines clarification – antihistamines Medsafe website Safety information: Use of cough and cold medicines in children – new advice Medicines for Alimemazine Diphenhydramine consideration Brompheniramine Doxylamine Chlorpheniramine Meclozine Cyclizine Promethazine Dexchlorpheniramine New Zealand Some oral sedating antihistamines available without exposure to a prescription (pharmacist-only and pharmacy only), sedating therefore usage data is not easily available. antihistamines Table of Contents 1.0 PURPOSE ......................................................................................................................................
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • UQ272429 OA.Pdf
    Cochrane Database of Systematic Reviews Oral antihistamine-decongestant-analgesic combinations for the common cold (Review) De Sutter AIM, van Driel ML, Kumar AA, Lesslar O, Skrt A De Sutter AIM, van Driel ML, Kumar AA, Lesslar O, Skrt A. Oral antihistamine-decongestant-analgesic combinations for the common cold. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD004976. DOI: 10.1002/14651858.CD004976.pub3. www.cochranelibrary.com Oral antihistamine-decongestant-analgesic combinations for the common cold (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 3 OBJECTIVES ..................................... 3 METHODS ...................................... 4 RESULTS....................................... 5 Figure1. ..................................... 7 Figure2. ..................................... 8 DISCUSSION ..................................... 19 AUTHORS’CONCLUSIONS . 20 ACKNOWLEDGEMENTS . 20 REFERENCES ..................................... 21 CHARACTERISTICSOFSTUDIES . 24 DATAANDANALYSES. 64 Analysis 1.1. Comparison 1 Combination 1: Antihistamine-decongestant, Outcome 1 Global evaluation. 66 Analysis 1.2. Comparison 1 Combination 1: Antihistamine-decongestant, Outcome 2 Side effects: all - Combination 1: Antihistamine-decongestant. 67 Analysis 1.3. Comparison 1 Combination 1: Antihistamine-decongestant,
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • 209089Orig1s000 209090Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209089Orig1s000 209090Orig1s000 CLINICAL REVIEW(S) CLINICAL REVIEW Application Type NDA (Rx to OTC switch) Application Number(s) 209-089 Xyzal Allergy 24 HR tablets 209-090 Xyzal Allergy 24 HR solution Priority or Standard Standard Submit Date(s) March 18, 2016 Received Date(s) March 31, 2016 PDUFA Goal Date January 31, 2017 Division / Office DPARP/ODE 2/OND Reviewer Name(s) Xu Wang, M.D., Ph.D. Review Completion Date December 9, 2016 Established Name Levocetirizine dihydrochloride Rx Trade Name Xyzal tablets/solution OTC Trade Name Xyzal Allergy 24HR tablets/solution Therapeutic Class Antihistamine Applicant UCB Inc. Formulation(s) tablets/solution Dosing Regimen ≥12 years: One tablet (5 mg) daily/10 mL solution (5 mg) daily; 1 6 – 11 years: /2 tablet (2.5 mg) daily/5 mL solution (2.5 mg) daily; 2 – 5 years: 2.5 mL solution (1.25 mg) daily Indication(s) Temporarily relieve these symptoms due to hay fever or other upper respiratory allergies: • running nose, • sneezing, • itchy, watering eyes, • itching of nose or throat Intended Population(s) Tablets: ≥6 years of age Solution: ≥2 years of age Template Version: March 6, 2009 Reference ID: 4025819 Clinical Review Xu Wang, M.D., Ph.D. NDA 209-089/NDA 209-090 Rx to OTC switch Xyzal Allergy 24HR (levocetirizine dihydrochloride) tablets/solution Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT .........................................4 1.1 Recommendation on Regulatory Action ............................................................. 4 1.2 Risk Benefit Assessment .................................................................................... 4 2 INTRODUCTION AND REGULATORY BACKGROUND ........................................ 4 2.1 Product Information ............................................................................................ 4 2.2 Currently Available Treatments for Proposed Indications..................................
    [Show full text]
  • Using Medications, Cosmetics, Or Eating Certain Foods Can Increase Sensitivity to Ultraviolet Radiation
    USING MEDICATIONS, COSMETICS, OR EATING CERTAIN FOODS CAN INCREASE SENSITIVITY TO ULTRAVIOLET RADIATION. INDIVIDUALS SHOULD CONSULT A PHYSICIAN BEFORE USING A SUNLAMP, IF THEY ARE TAKING MEDICATIONS. THE ITEMS LISTED ARE POTENTIAL PHOTOSENSITIZING AGENTS THAT MAY INCREASE SENSITIVITY TO ULTRAVIOLET LIGHT THAT MAY RESULT IN A PHOTOTOXIC OR PHOTOALLERGIC RESPONSES. PHOTOSENSITIZING MEDICATIONS Acetazolamide Amiloride+Hydrochlorothizide Amiodarone Amitriptyline Amoxapine Astemizole Atenolol+Chlorthalidone Auranofin Azatadine (Optimine) Azatidine+Pseudoephedrine Bendroflumethiazide Benzthiazide Bromodiphenhydramine Bromopheniramine Captopril Captopril+Hydrochlorothiazide Carbaamazepine Chlordiazepoxide+Amitriptyline Chlorothiazide Chlorpheniramine Chlorpheniramin+DPseudoephedrine Chlorpromazine Chlorpheniramine+Phenylopropanolamine Chlorpropamide Chlorprothixene Chlorthalidone Chlorthalidone+Reserpine Ciprofloxacin Clemastine Clofazime ClonidineChlorthalisone+Coal Tar Coal Tar Contraceptive (oral) Cyclobenzaprine Cyproheptadine Dacarcazine Danazol Demeclocycline Desipramine Dexchlorpheniramine Diclofenac Diflunisal Ditiazem Diphenhydramine Diphenylpyraline Doxepin Doxycycline Doxycycline Hyclate Enalapril Enalapril+Hydrochlorothiazide Erythromycin Ethylsuccinate+Sulfisoxazole Estrogens Estrogens Ethionamide Etretinate Floxuridine Flucytosine Fluorouracil Fluphenazine Flubiprofen Flutamide Gentamicin Glipizide Glyburide Gold Salts (compounds) Gold Sodium Thiomalate Griseofulvin Griseofulvin Ultramicrosize Griseofulvin+Hydrochlorothiazide Haloperidol
    [Show full text]
  • Ghany NIDDK HCV DAA COOP ISR Draft Protocol
    CLINICAL RESEARCH PROTOCOL NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES DATE: August 17, 2018 CLINICAL PROTOCOL NO.: 14-DK-0084 TITLE: Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl Alone or in Combination with Ribavirin in Patients with Chronic Hepatitis C SHORT TITLE: Chlorcyclizine HCl for Chronic Hepatitis C IDENTIFYING WORDS: Chlorcyclizine HCl, Ribavirin, Direct Acting Antivirals, Chronic Hepatitis C PRINCIPAL INVESTIGATOR: Christopher Koh, M.D., MHSc, Liver Diseases Branch (LDB), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) RESPONSIBLE INVESTIGATOR: T. Jake Liang, M.D., Chief, LDB, NIDDK ASSOCIATE INVESTIGATORS: Theo Heller, M.D., Investigator, LDB, NIDDK Yaron Rotman, M.D. Investigator, LDB, NIDDK Marc Ghany, M.D. Investigator, LDB, NIDDK Elenita Rivera, R.N., Research Nurse, LDB, NIDDK ESTIMATED DURATION OF STUDY: 3 Years NUMBER AND TYPE OF PATIENTS: 50 patients with chronic hepatitis C, ages above 18 years, both male and female SUBJECTS OF STUDY: Number of patients: 50 Sex: Male & Female Age Range: Above 18 years Volunteers: None PROJECT USES IONIZING RADIATION: Yes, for medical indications only. PROJECT USES "DURABLE POWER OF ATTORNEY": No Version: 08/11/14 2 OFF-SITE PROJECT: No MULTI-INSTITUTIONAL PROJECT: No Version: 08-17-2018 3 Précis Up to 50 patients with chronic hepatitis C, who are treatment naïve or relapsers to any interferon/ribavirin regimen will be enrolled into this pilot study evaluating chlorcyclizine HCl with or without ribavirin (RBV) as antiviral therapy. Adult patients (≥18 years of age) with evidence of active chronic hepatitis C infection (all genotypes) with detectable HCV RNA in serum >10,000 IU/mL without contraindications to chlorcyclizine HCl or ribavirin or evidence/history of hepatic decompensation will be enrolled.
    [Show full text]
  • Medications to Avoid in Long QT Syndrome
    Jackie Crawford Cardiac Inherited Disease Co-ordinator C/- Paediatric Cardiology; Level 3 Starship; Auckland City Hospital Private Bag 92024; Auckland Cardiac Inherited Disease Registry Phone: (09) 3074949 ext 23634 www.cidg.org Fax: (09) 6309877 Email: [email protected] Medications to be avoided, or requiring special caution, in people with Long QT syndrome This list includes medications which prolong the QT interval and is meant as a guide for people with Long QT syndrome, or acquired long QT interval from heart muscle disease, and their parents or guardians. It should not be seen as all inclusive. Those prescribing any medication to someone with Long QT syndrome should always check the drug specifications and contra-indications. The list has been compiled by review of publications and/or drug advice sheets provided with medications. Check also www.SADS.org and www.Torsades .org. Antibiotics Erythromycin, Clarithromycin, Gatifloxacin, levofloxacin, Moxifloxacin Sulfamethoxazole-trimethoprim (Septrin/Bactrim), Spiramycin, Pentamidine Antihistamines Terfenadine, Astemizole, Diphenhydramine, (These are particularly to be avoided (even in normal subjects) in combination with Erythromycin or grapefruit juice or the antifungals ketoconazole, miconazole, fluconazole or itraconazole) [Antihistamines that may be used safely are loratidine, cetirizine and fexofenadine, and phenergan] Appetite suppressants Fenfluramine, phentermine, Sibutramine Asthma treatments The Beta-2 agonists (e.g. Terbutaline, Salbutamol, Salmeterol) both work against
    [Show full text]